BioCentury
ARTICLE | Clinical News

APL-2: Phase I started

February 23, 2015 8:00 AM UTC

Apellis began the open-label, dose-escalation, international Phase I ASAP II trial to evaluate single intravitreal doses of 4, 10 and 20 mg APL-2 in about 18 patients. Safety data are expected in May-...